LAMP Cancer Antigen Constructs for Targeted MHCII Presentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing DNA vaccines for cancer and hyperproliferative disorders suffer from low immunogenicity due to stochastic access of epitopes to the MHCII presentation pathway, and the efficacy of LAMP Constructs is unpredictable based on antigen sequences, making it difficult to predict immune responses and increasing production costs.
Innovation Solution
Development of improved LAMP Constructs comprising specific fragments and variants of LAMP domains that effectively target cancer antigens to the lysosomal/endosomal compartment, enhancing immune responses by preferentially stimulating helper T cells and generating antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional DNA vaccines are used, then safety is maintained and vector backbone immunity is avoided, but immunogenicity is low due to stochastic access of epitopes to MHCII presentation pathway
Solution Approach 1:
The patent introduces LAMP-1 as an intermediary protein that mediates between the antigen and the MHCII presentation pathway. The LAMP-1 construct includes a signal sequence, transmembrane domain, and cytoplasmic tail that facilitates targeted delivery of cancer antigens to endosomal/lysosomal compartments, thereby enhancing epitope access to MHCII molecules and improving immunogenicity while maintaining safety.
Solution Approach 2:
The patent modifies the delivery parameters of the antigen by changing from conventional DNA vaccine delivery to LAMP-1 mediated cellular delivery. The LAMP-1 construct alters the subcellular localization and processing parameters, directing antigens to specific compartments where they are more effectively presented to T cells, thus enhancing immunogenicity without compromising safety.
2Reliability
If complete LAMP Constructs are used, then antigen targeting to lysosomal compartment is achieved, but efficacy is unpredictable based on antigen sequences and production costs increase
Solution Approach 1:
The patent segments the LAMP-1 construct into functional domains: signal sequence, transmembrane domain, and cytoplasmic tail. This segmentation allows for modular design where the core LAMP-1 structure provides reliable targeting, while antigen sequences can be independently optimized for immunogenicity, improving both predictability and manufacturing efficiency.
Solution Approach 2:
The patent employs standardized LAMP-1 construct templates that can be reused across different cancer antigens. By copying the proven LAMP-1 framework and only substituting the antigenic sequences, the patent maintains reliable targeting efficiency while improving predictability of immune responses and reducing production costs through template-based cloning.
3Device complexity
If stochastic epitope access to MHCII pathway is used, then simple vaccine design is maintained, but immune response is insufficient and treatment effectiveness is limited
Solution Approach 1:
The LAMP-1 construct serves as an intermediary that actively mediates epitope access to the MHCII pathway. The cytoplasmic tail of LAMP-1 interacts with endosomal/lysosomal compartments, creating a controlled pathway for antigen processing and presentation, thereby significantly enhancing immune response magnitude while adding only moderate complexity to the vaccine design.
Solution Approach 2:
The LAMP-1 construct performs preliminary action by pre-positioning the antigen in the endosomal/lysosomal compartment before MHCII presentation occurs. This preliminary targeting and processing step ensures that epitopes are readily available for T cell recognition, thereby enhancing immune response without requiring complex multi-component vaccine designs.
Data Source
AI summary
The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and/or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.